Academic research centers from Finland and California come together thanks to a Department of Defense Breast Cancer Research Program (BRCP) Breakthrough Award to help advance breast cancer research while supporting tighter ties between the Scandinavian and California investigators. Thanks to $5.2 million from the U.S. Department of Defense the University of Helsinki in partnership with University of California, San Francisco lead a study involving teams of researchers, clinicians and advocates the investigation into how the MYC oncogene can regulate an anti-tumor immune response and hopefully leading to novel therapeutic approaches targeting aggressive breast cancers.
The Yin and Yang of MYC Oncogene
While some cancer genes support cancerous growth, they also contribute to vulnerabilities in the same cancer cells which the Finish and Californian team hope to exploit with novel therapies. For example, in breast cancer MYC cancer gene reprograms cells to grow without pause however this uncontrolled growth renders MYC carrying cancer cells prey to a number of drugs.
Quest for Precision
Highlighting the opportunity, Juha Klefstrom, PhD from University of Helsinki rec...
Note: If you need assistance with your subscription or would like to discuss a corporate subscription for more than 10 employees please contact us or use the chat (bottom right).